BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced an inducement grant awarded December 10, 2025 under BBOT’s 2025 Inducement Plan for an individual hired in November 2025.
The award comprises non-qualified stock options to purchase 53,060 shares at an exercise price of $12.88 per share (the Nasdaq closing price on the grant date). Options vest 25% after one year and the remainder in 36 equal monthly installments, subject to continued service.
The 2025 Inducement Plan was adopted by the board in October 2025 and the compensation committee (all independent directors) approved the Awards as a material inducement under Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – BBOT
On Dec 12, the first trading day after this news, BBOT closed 1.95% below the previous close.
Data tracked by StockTitan Argus for the Dec 12 session.
Key Figures
- Inducement options granted
- 53,060 shares
- Non-qualified stock options under 2025 Inducement Plan
- Option exercise price
- $12.88 per share
- Exercise price set at Nasdaq closing price on Dec 10, 2025
- Par value
- $0.0001 per share
- Par value of BBOT common stock referenced in grant
- Vesting schedule
- 25% after 1 year, then 36 monthly installments
- Subject to continued service with the company
Historical Context
-
Late-breaking BBO-10203 preclinical data presented at SABCS.
-
Planned presentations at two December investor healthcare conferences.
-
Q3 2025 results, cash runway into 2028, pipeline progress update.
-
Jefferies Global Healthcare Conference presentation announcement.
-
Announcement of BBO-10203 poster presentations at SABCS.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement grant financial
non-qualified stock options financial
equity incentive plans financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025.
The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value
All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.